Last reviewed · How we verify

NCT06354712

Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.

Recruiting now Phase 2 Last updated 15 January 2025
What this trial tests

Phase 2 trial testing N-Acetyl-Cysteine with Institutional standard care in Oral Mucositis (Ulcerative) Due to Radiation in 50 participants. Currently enrolling.

Timeline
4 April 2024
Primary endpoint
1 March 2025
1 March 2025

Quick facts

Lead sponsorMansoura University
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment50
Start date4 April 2024
Primary completion1 March 2025
Estimated completion1 March 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Mansoura University

Who can join

Adults 18 to 80, any sex, with Oral Mucositis (Ulcerative) Due to Radiation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of N-acetylcysteine in the prevention of radiotherapy induced oral mucositis in Head and Neck cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Oral Mucositis (Ulcerative) Due to Radiation

Currently open trials in the same condition.

Other Mansoura University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06354712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing